AGP Executive Report
Last update: 19 minutes agoHidradenitis Suppurativa Drug Value: A new JAMA Dermatology analysis using cost-efficiency frontier methods ranks adalimumab as the most cost-efficient biologic (40mg weekly) versus secukinumab and bimekizumab across trial-style outcomes in France and other major markets. Ebola Response in Congo: WHO chief Tedros returns to the DRC as the Bundibugyo-related Ebola situation expands, with calls to rapidly scale medical care, surveillance and safe burials amid insecurity and lack of approved tools for this strain. Digital Health Regulation Watch: “Vital Signs” spotlights how AI and digital health regulation are converging, warning about AI-washing in health tech deals and surveying new enforcement and guidance across the US, EU and UK. Clinical Trials Update: Canada has authorized Moderna to start Phase 1 trials of an mRNA vaccine targeting the Bundibugyo Ebola strain, with manufacturing planned in Canada. Public Health & Risk: A report argues Australia should move faster on targeted H5N1 wildlife vaccination to prevent local extinctions, not just rely on pilots. Care Access Story: A Quebec donor shares how weekly plasma donations support treatments for rare conditions like Guillain-Barré, underscoring the role of blood services in patient care.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![[Latest] Global Generative AI In Clinical Trials Market Size/Share Worth USD 1.86 Billion by 2035 at a 9.63% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/21273967-731329129-cmi-logo-png-100x51.png){kind=logo}
